Estudio comparativo de mundo real sobre la eficacia de los inhibidores de la quinasa Janus en pacientes con artritis reumatoide: El estudio de cohortes ANSWER
Rheumatology 2023 doi 10.1093/rheumatology/kead543
This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.